Liver Injury/Regeneration News

The FDA granted BioVie Inc. orphan drug designation for BIV201 for the treatment of ascites in all instances except those caused by cancer, according to the company.

Women  may be more likely to develop alcoholic liver disease, even among those who drink less alcohol than men. Further, women who drink similar amounts of alcohol as men may be more likely to develop liver injury, according to research recently published in Alcoholism: Clinical and Experimental Research.

In a case-control study, Asian patients with HIV without hepatitis B or C virus infection showed high rates of liver fibrosis and fatty liver compared with patients without HIV.

Developing drug-induced liver injury from Sustiva-based antiretroviral therapy is a rare occurrence; however, researchers found that some South African patients treated with it experienced severe liver injury, which ultimately led to mortality.

SAN DIEGO —  Despite increased rates of acetaminophen-induced acute liver injury and acute liver failure than male counterparts, women did not experience poorer survival outcomes related to these conditions, according to findings presented at Digestive Disease Week 2016.

BARCELONA — New research presented at the International Liver Congress showed universal screening for alcohol in hospital settings may be able to identify individuals at greatest risk for alcohol-related harm, and, in turn, reduce the risk for more severe liver damage in the future.

Patients with complementary and alternative medicines-induced liver injury had higher rates of liver transplantation compared with prescription medication-induced injury. Additionally, a lower transplant-free survival was observed, according to recently published findings.

The NIH National Institutes of Diabetes and Digestive and Kidney Diseases awarded $703,620 to Ajay Jain, MD, pediatric hepatologist and medical director of the pediatric liver transplant program at SSM Health Cardinal Glennon Children's Hospital, and researcher at Saint Louis University, for research in preventing damage to the liver and gut from parenteral nutrition-associated disorders, according to a press release.

InSphero AG announced it has launched their newest liver model, 3D InSight Multi-Donor Human Liver Microtissues, to help predict drug-induced liver injury in clinical drug trials, according to a press release.

Researchers in India found that an association between drug-induced liver injury and Stevens-Johnson syndrome/toxic epidermal necrolysis was rare, according to published findings.